60 Chapter 4 Total N = 712 Part 1 Q4 2011–Q1 2014 N = 191 Part 2 Q1 2014– Q1 2016 N = 334 Part 3 Q2 2016– Q2 2018 N = 187 p value 6 Anal sphincter involvement Reported 7.9% (56) 3.7% (7) 8.4% (28) 11.2% (21) 0.004 Not reported 92.1% (656) 96.3% (184) 91.6% (306) 88.7% (166) in low tumours 33.7% (240) 42.9% (82) 31.4% (105) 28.3% (53) in mid/high tumours (N/A) 58.4% (416) 53.4% (102) 60.2% (201) 60.4% (113) 7 MRF invasion Reported 81.4% (580) 73.3% (140) 82.9% (277) 87.2% (163) 0.032 Not reported 16.6% (118) 24.1% (46) 15.0% (50) 11.7% (22) in cT3-4 tumours# 8.6% (61) 11.0% (21) 7.5% (25) 8.0% (15) in cT1-2 tumours (N/A)# 7.4% (53) 12.6% (24) 6.9% (23) 3.2% (6) Inconclusive** 2.0% (14) 2.6% (5) 2.1% (7) 1.1% (2) 8 Tumour-MRF margin Reported 59.7% (426) 48.7% (93) 65.6% (219) 61.0% (114) 0.004 Not reported 40.2% (286) 51.3% (98) 34.5% (115) 39.0% (73) in cT3-4 tumours# 28.2% (201) 36.1% (69) 22.2% (74) 31.0% (58) in cT1-2 tumours (N/A)# 11.4% (81) 14.7% (28) 11.7% (39) 7.5% (14) 9 cN-stage Reported incl. substaging (cN0/cN1abc/cN2ab) 1.3% (9) 0.5% (1) 2.4% (8) 0% (0) <0.001 Reported as cN0/N1/N2 74.2% (528) 58.1% (111) 74.6% (249) 89.8% (168) Reported as cN-/N+ 6.3% (45) 1.6% (3) 10.8% (36) 3.2% (6) Not explicitly mentioned but can be derived from prose description of number of suspicious nodes 11.1% (79) 19.4% (37) 9.0% (30) 6.4% (12) Not reported 7.2% (51) 20.4% (39) 3.3% (11) 0.5% (1) 10 Number of N+ nodes (in cN+ cases) Reported 54.9% (391) 41.9% (80) 57.5% (192) 63.6% (119) 0.014 Not reported 12.9% (92) 15.7% (30) 13.5% (45) 9.1% (17) Table 2 Continued
RkJQdWJsaXNoZXIy MjY0ODMw